Anumana, a portfolio company of nference, has announced Maulik Nanavaty as its new chief executive officer and a member of its board of directors.
Anumana and nference co-founder Murali Aravamudan will continue to work as CEO of nference and has now transitioned to executive chairman of the Anumana board of directors.
Nanavaty will lead Anumana through a growth period as the company commences deployment and commercialisation of its ECG-AI platform technology.
Prior to joining Anumana, Nanavaty worked at Boston Scientific as senior vice-president and president of Neuromodulation.
At Boston Scientific, he led the development and commercialisation of microelectronic implantable technologies and software for treating neurological diseases and other chronic conditions.
He served as president of Boston Scientific Japan and as vice-president and general manager of interventional cardiology.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Nanavaty also worked at Baxter International and served there for 16 years in various executive positions.
Nanavaty said: “Anumana’s mission to unlock the electrical language of the heart in order to improve patient care is incredibly inspiring and I am grateful for the opportunity to lead its continued progress.
“The company has accomplished fast-paced disruptive innovation within just two years since its founding, in close partnership with Mayo Clinic‘s world-renowned cardiologists and business collaborators.
“Together, we will build on and accelerate this evidence-based innovative platform, bringing our unique AI-based portfolio of cardiac disease-related products to market globally, with real-world evidence in transforming patient outcomes.”
In addition to his role as CEO of Anumana, Nanavaty will also continue to work as a board member of Rani Therapeutics.
